Viracta Therapeutics Inc. (NASDAQ:VIRX) traded at $2.89 at close of the session on Friday, 02/18/22, made a downward move of -1.37% on its previous day’s price.

Looking at the stock we see that its previous close was $2.93 with the day’s price range being $2.76 – $2.97. In terms of its 52-week price range, VIRX has a high of $24.80 and a low of $2.18. The company’s stock has gained about 4.71% over that past 30 days.

3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Viracta Therapeutics Inc. has a market cap of $113.81 million and is expected to release its quarterly earnings report on Nov 10, 2021. Estimates by analysts give the company expected earnings per share (EPS) of -$0.46, with the EPS growth for the year raised at -$3.7 for 2021 and -$1.35 for next year. These figures represent 31.00% and 63.50% growth in EPS for the two years respectively.

There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the VIRX stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 100% Sell. Long term indicators on average place the stock in the category of 100% Sell.

Based on estimates by 5 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the Viracta Therapeutics Inc. (VIRX) stock as a Hold, while 5 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.

Looking further, we note the current price level is 6.32% off its SMA20 and -10.05% from its 50-day simple moving average. The RSI (14) is pointing at 48.40 while the volatility over the past week is 8.99% and jumps to 12.29% over the past one month. The beta value is 2.15, while the average true range (ATR) is currently pointing at 0.29. The average price target for the stock over the next 12 months is $27.40, with the estimates having a low of $10.00 and a high of $45.00. These price ends are -246.02% and -1457.09% off the current price level respectively, although investors could be excited at the prospect of a -1111.07% if the VIRX share price touches on the median price of $35.00.

Coming back to Viracta Therapeutics Inc. (NASDAQ:VIRX), we note that the average 3-month trading volume was 311.21K. Current shares outstanding are 37.35 million.

The insiders hold 1.90% of the company’s shares while institutions hold 52.10%. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -20.82% down in year-to-date price movement.

Leave a Reply

Your email address will not be published. Required fields are marked *